Skip Navigation


JAC Advance Access originally published online on December 4, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/1/113    most recent
dkh022v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Groll, A. H.
Right arrow Articles by Vormoor, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groll, A. H.
Right arrow Articles by Vormoor, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 113-114
© 2004 The British Society for Antimicrobial Chemotherapy

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation

Andreas H. Groll*, Hedwig Kolve, Karoline Ehlert, Michael Paulussen and Josef Vormoor

Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology/Oncology, University Children’s Hospital, Domagkstrasse 9a, 48129 Münster, Germany

Received 6 October 2003; accepted 13 October 2003

Voriconazole is a novel antifungal triazole that undergoes extensive oxidative metabolization involving several CYP450 isoenzymes. We report the case of a 14-year-old patient who received voriconazole concomitant with ciclosporin A as secondary antifungal prophylaxis after bone marrow transplantation. Temporary discontinuation of voriconazole due to worsening liver function tests (LFTs) resulted in a sudden drop of ciclosporin A trough levels in blood. Ciclosporin A trough levels returned to baseline following normalization of LFTs and re-institution of voriconazole. This report emphasizes the need for careful monitoring and dose adjustments of ciclosporin A in patients receiving concomitant voriconazole, and in whom voriconazole is discontinued in order to prevent subtherapeutic ciclosporin A levels with the potential consequence of graft-versus-host disease.

Keywords: antifungals, CYP450 isoenzymes, graft-versus-host disease

* Corresponding author. Tel: +49-251-835-2801; Fax: +49-251-835-2804; E-mail: grollan{at}mednet.uni-muenster.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
K. Allinson, H. Kolve, H. G. Gumbinger, H. J. Vormoor, K. Ehlert, and A. H. Groll
Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients
J. Antimicrob. Chemother., March 1, 2008; 61(3): 734 - 742.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. Eiden, H. Peyriere, M. Cociglio, S. Djezzar, S. Hansel, J.-P. Blayac, D. Hillaire-Buys, and for the Network of the French Pharmacovigilance Ce
Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database
Ann. Pharmacother., May 1, 2007; 41(5): 755 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Vanden Bossche, J. Ausma, H. Bohets, K. Vermuyten, G. Willemsens, P. Marichal, L. Meerpoel, F. Odds, and M. Borgers
The Novel Azole R126638 Is a Selective Inhibitor of Ergosterol Synthesis in Candida albicans, Trichophyton spp., and Microsporum canis
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3272 - 3278.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.